CA1176573A - Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique - Google Patents

Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique

Info

Publication number: CA1176573A
Authority: CA; Canada
Prior art keywords: plasma; macromolecules; stream; filter; blood
Prior art date: 1980-05-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000436233A

Other languages

English (en)

Inventor

Paul S. Malchesky

Yukihiko Nose

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Japan Foundation for Artificial Organs

Original Assignee

Japan Foundation for Artificial Organs

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-05-29

Filing date

1983-09-07

Publication date

1984-10-23

1980-05-29 Priority claimed from US06/154,581 external-priority patent/US4350156A/en

1983-09-07 Application filed by Japan Foundation for Artificial Organs filed Critical Japan Foundation for Artificial Organs

1983-09-07 Priority to CA000436233A priority Critical patent/CA1176573A/fr

1984-10-23 Application granted granted Critical

1984-10-23 Publication of CA1176573A publication Critical patent/CA1176573A/fr

Status Expired legal-status Critical Current

Links

229920002521 macromolecule Polymers 0.000 title claims abstract description 56
238000000034 method Methods 0.000 title claims abstract description 30
238000001914 filtration Methods 0.000 title claims abstract description 22
239000012530 fluid Substances 0.000 title claims abstract description 13
239000012528 membrane Substances 0.000 claims abstract description 39
238000000926 separation method Methods 0.000 claims abstract description 11
230000015572 biosynthetic process Effects 0.000 claims abstract description 5
230000001413 cellular effect Effects 0.000 claims description 11
238000004891 communication Methods 0.000 claims description 8
230000006854 communication Effects 0.000 claims description 8
239000008139 complexing agent Substances 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
201000010099 disease Diseases 0.000 abstract description 30
210000004369 blood Anatomy 0.000 abstract description 20
239000008280 blood Substances 0.000 abstract description 20
238000011282 treatment Methods 0.000 abstract description 12
230000017531 blood circulation Effects 0.000 abstract description 4
230000001225 therapeutic effect Effects 0.000 abstract description 3
239000000243 solution Substances 0.000 description 28
210000004379 membrane Anatomy 0.000 description 20
108010088751 Albumins Proteins 0.000 description 14
102000009027 Albumins Human genes 0.000 description 14
238000001816 cooling Methods 0.000 description 12
108010091326 Cryoglobulins Proteins 0.000 description 9
238000002616 plasmapheresis Methods 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
239000011148 porous material Substances 0.000 description 7
238000001556 precipitation Methods 0.000 description 7
206010039073 rheumatoid arthritis Diseases 0.000 description 7
238000007873 sieving Methods 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
239000000047 product Substances 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
108010044091 Globulins Proteins 0.000 description 4
102000006395 Globulins Human genes 0.000 description 4
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
201000000564 macroglobulinemia Diseases 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
206010028417 myasthenia gravis Diseases 0.000 description 4
230000008569 process Effects 0.000 description 4
239000002594 sorbent Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
208000035150 Hypercholesterolemia Diseases 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000007710 freezing Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
208000006575 hypertriglyceridemia Diseases 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
241000721454 Pemphigus Species 0.000 description 2
206010036105 Polyneuropathy Diseases 0.000 description 2
206010037549 Purpura Diseases 0.000 description 2
241001672981 Purpura Species 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
231100000076 Toxic encephalopathy Toxicity 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000010924 continuous production Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010586 diagram Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
238000005374 membrane filtration Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
230000007824 polyneuropathy Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000010792 warming Methods 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
235000001674 Agaricus brunnescens Nutrition 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000237074 Centris Species 0.000 description 1
108010075016 Ceruloplasmin Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
206010010075 Coma hepatic Diseases 0.000 description 1
206010011686 Cutaneous vasculitis Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
240000003550 Eusideroxylon zwageri Species 0.000 description 1
229940124135 Factor VIII inhibitor Drugs 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
102000014702 Haptoglobin Human genes 0.000 description 1
108050005077 Haptoglobin Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019939 Herpes gestationis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
208000024781 Immune Complex disease Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
206010022491 Insulin resistant diabetes Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
108010061952 Orosomucoid Proteins 0.000 description 1
102000012404 Orosomucoid Human genes 0.000 description 1
208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000005587 Refsum Disease Diseases 0.000 description 1
206010063676 Rhesus incompatibility Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010047505 Visceral leishmaniasis Diseases 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
208000030597 adult Refsum disease Diseases 0.000 description 1
239000000910 agglutinin Substances 0.000 description 1
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000019628 coolness Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
238000002615 hemofiltration Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
201000001059 hepatic coma Diseases 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
101150026046 iga gene Proteins 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1

Landscapes

External Artificial Organs (AREA)

CA000436233A 1980-05-29 1983-09-07 Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique Expired CA1176573A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000436233A CA1176573A (fr)	1980-05-29	1983-09-07	Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US06/154,581 US4350156A (en)	1980-05-29	1980-05-29	Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US154,581		1980-05-29
CA000377362A CA1163517A (fr)	1980-05-29	1981-05-12	Methode et appareil pour l'extraction continue, par filtration de macromolecules contenues dans un liquide physiologique
CA000436233A CA1176573A (fr)	1980-05-29	1983-09-07	Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000377362A Division CA1163517A (fr)	1980-05-29	1981-05-12	Methode et appareil pour l'extraction continue, par filtration de macromolecules contenues dans un liquide physiologique

Publications (1)

Publication Number	Publication Date
CA1176573A true CA1176573A (fr)	1984-10-23

Family

ID=27167055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000436233A Expired CA1176573A (fr)	1980-05-29	1983-09-07	Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique

Country Status (1)

Country	Link
CA (1)	CA1176573A (fr)

1983
- 1983-09-07 CA CA000436233A patent/CA1176573A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2001-10-23	MKEX	Expiry

Publication	Publication Date	Title
US4350156A (en)	1982-09-21	Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
Falkenhagen et al.	1999	Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances
EP0038203B1 (fr)	1985-07-24	Dispositif pour le traitement du sang
CA1086235A (fr)	1980-09-23	Systeme d'elimination continue de substances contenues dans le sang par circulation extracorporelle
US4966709A (en)	1990-10-30	Thermofiltration of plasma
CA1234523A (fr)	1988-03-29	Procede et appareil pour la separation du plasma
US5080796A (en)	1992-01-14	Thermofiltration of plasma
Stegmayr	2001	Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome
Lysaght et al.	2019	Closed-loop plasmapheresis
Agishi et al.	2000	Double filtration plasmapheresis
Nosé et al.	1985	Clinical thermofiltration: initial application
US5217618A (en)	1993-06-08	Plasma purification treatment
Ronco et al.	1996	Basic mechanisms and definitions for continuous renal replacement therapies
CA1176573A (fr)	1984-10-23	Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique
Siami et al.	2001	Current topics on cryofiltration technologies
Behm et al.	1989	Selective and specific adsorbents for medical therapy
Borberg	1981	Problems of plasma exchange therapy
Castino et al.	1978	The filtration of plasma from whole blood: A novel approach to clinical detoxification
Malchesky et al.	1981	Macromolecule removal from blood
CA1176574A (fr)	1984-10-23	Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique
CA1170138A (fr)	1984-07-03	Methode et appareil pour debarrasser un liquide physiologique en circulation de ses macromolecules par filtration
Samtleben et al.	1987	Ex vivo and in vivo protein A perfusion: background, basic investigations, and first clinical experiences
US5057226A (en)	1991-10-15	Treatment of liquid including blood components
Malchesky	1996	8.3 EXTRACORPOREAL ARTIFICIAL ORGANS
Smith et al.	1984	Membrane plasmapheresis and the developing technology of plasma therapy